All In Biotech

Drug Trial Radar · NCT04720326

Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Multicentre, Open-Label, Randomised, Two-Arm, Parallel-Group, Superiority Study to Assess Bioavailability and Practicability of Envarsus® Compared With Advagraf® in de Novo Liver Transplant Recipients (EnGraft)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

268

Actual

Start

Dec 23, 2020

Primary completion

Jan 25, 2024

Study completion Oct 29, 2026

Sponsor

Lead sponsor
Edward GeisslerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chiesi Pharmaceuticals GmbH; Excelya
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial participants are randomised within 14 days after liver transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus® (test arm) or Advagraf® (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to assess drug bioavailability and the ease and accuracy of achieving the targeted blood concentration range. Dose-normalised trough level (concentration/dose ratio) is measured at 12 weeks post-randomisation as an estimate of tacrolimus bioavailability. It is hypothesised that treatment with Envarsus® will confer a superior (higher) C/D ratio after 12 weeks of therapy owing to the superior bioavailability of this galenic drug formulation (proprietary MeltDose® technology). To test whether an elevated C/D ratio is also associated with improved clinical outcomes, a range of other pharmacokinetic, efficacy and safety variables are evaluated at 10 study visits spanning a period of 3 years.

Conditions

  • Prophylaxis Against Liver Transplant Rejection

Interventions

  • Tacrolimus PillDrug

    Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.

  • Tacrolimus capsuleDrug

    Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)Time frame: 12 weeks post-randomisation

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital Aachen

    Aachen, Germany

  • Charite - University Medicine Berlin

    Berlin, Germany

  • University Hospital Essen

    Essen, Germany

  • University Hospital Frankfurt

    Frankfurt, Germany

  • University Hospital Hamburg Eppendorf

    Hamburg, Germany

  • Hannover Medical School

    Hanover, Germany

  • University Hospital Heidelberg

    Heidelberg, Germany

  • University Hospital Jena

    Jena, Germany

  • University Hospital Schleswig-Holstein - Campus Kiel

    Kiel, Germany

  • University Hospital Leipzig

    Leipzig, Germany

  • University Hospital Magdeburg

    Magdeburg, Germany

  • University Hospital Mainz

    Mainz, Germany

  • University Hospital Muenster

    Münster, Germany

  • University Hospital Regensburg

    Regensburg, Germany

  • University Hospital Tuebingen

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.